181629-93-6 Usage
Description
N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE is a complex organic compound with a unique molecular structure. It is characterized by its fluoro and pyrindyl groups, as well as its dihydro, methoxy, and trifluoromethyl moieties. N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE has potential applications in various fields due to its specific chemical properties and interactions.
Uses
1. Used in Pharmaceutical Applications:
N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE is used as a pharmaceutical agent for the treatment of irritable bowel syndrome (IBS). It functions as a SR-2C/SR-2B receptor antagonist, which helps in managing the symptoms associated with IBS by modulating the activity of specific receptors in the body.
2. Used in Chemical Research:
In the field of chemical research, N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE can be utilized as a starting material or intermediate for the synthesis of other complex organic compounds. Its unique structure and functional groups make it a valuable candidate for further chemical modifications and exploration of its potential applications.
3. Used in Material Science:
The compound may also find applications in material science, particularly in the development of new materials with specific properties. Its fluoro and trifluoromethyl groups could contribute to the compound's stability and reactivity, making it suitable for use in the creation of advanced materials with tailored characteristics.
4. Used in Analytical Chemistry:
N-[3-FLUORO-5-(3-PYRINDYL)PHENYL]-2,3-DIHYDRO-5-METHOXY-6-(TRIFLUOROMETHYL)-1H-INDOLE-1-CARBOXAMIDE can be employed as a reference compound or standard in analytical chemistry. Its distinct structure and properties make it suitable for use in the calibration of analytical instruments and the development of new analytical methods.
Biological Activity
5-HT 2C/2B receptor antagonist (pK i values are 7.0, 8.1 and 9.1 at 5-HT 2A , 2B and 2C receptors respectively). Displays inverse agonism in a 5-HT-stimulated PI hydrolysis model of 5-HT 2C receptor function. Orally active in vivo .
Check Digit Verification of cas no
The CAS Registry Mumber 181629-93-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,1,6,2 and 9 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 181629-93:
(8*1)+(7*8)+(6*1)+(5*6)+(4*2)+(3*9)+(2*9)+(1*3)=156
156 % 10 = 6
So 181629-93-6 is a valid CAS Registry Number.
InChI:InChI=1/C22H17F4N3O2/c1-31-20-9-13-4-6-29(19(13)11-18(20)22(24,25)26)21(30)28-17-8-15(7-16(23)10-17)14-3-2-5-27-12-14/h2-3,5,7-12H,4,6H2,1H3,(H,28,30)
181629-93-6Relevant articles and documents
A divergent SAR study allows optimization of a potent 5-HT2c inhibitor to a promising antimalarial scaffold
Calderon, Felix,Vidal-Mas, Jaume,Burrows, Jeremy,De La Rosa, Juan Carlos,Jimenez-Diaz, Maria Belen,Mulet, Teresa,Prats, Sara,Solana, Jorge,Witty, Michael,Gamo, Francisco Javier,Fernandez, Esther
, p. 373 - 377 (2012/06/30)
From the 13-533 chemical structures published by GlaxoSmithKline in 2010, we identified 47 quality starting points for lead optimization. One of the most promising hits was the TCMDC-139046, a molecule presenting an indoline core, which is well-known for its anxiolytic properties by interacting with serotonin antagonist receptors 5-HT2. The inhibition of this target will complicate the clinical development of these compounds as antimalarials. Herein, we present the antimalarial profile of this series and our efforts to avoid interaction with this receptor, while maintaining a good antiparasitic potency. By using a double-divergent structure-activity relationship analysis, we have obtained a novel lead compound harboring an indoline core.
Biarylcarbamoylindolines are novel and selective 5-HT(2C) receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3- pyridyl)oxy]5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent
Bromidge, Steven M.,Dabbs, Steven,Davies, David T.,Davies, Susannah,Duckworth, D. Malcolm,Forbes, Ian T.,Gaster, Laramie M.,Ham, Peter,Jones, Graham E.,King, Frank D.,Mulholland, Keith R.,Saunders, Damian V.,Wyman, Paul A.,Blaney, Frank E.,Clarke, Stephen E.,Blackburn, Thomas P.,Holland, Vicky,Kennett, Guy A.,Lightowler, Sean,Middlemiss, Derek N.,Trail, Brenda,Riley, Graham J.,Wood, Martyn D.
, p. 1123 - 1134 (2007/10/03)
The evolution, synthesis, and biological activity of a novel series of 5-HT(2C) receptor inverse agonists are reported. Biarylcarbamoylindolines have been identified with excellent 5-HT(2C) affinity and selectivity over 5- HT(2A) receptors. In addition, (pyridyloxypyridyl)carbamoylindolines have been discovered with additional selectivity over the closely related 5-HT(2B) receptor. Compounds from this series are inverse agonists at the human cloned 5-HT(2C) receptor, completely abolishing basal activity in a functional assay. The new series have reduced P450 inhibitory liability compared to a previously described series of 1-(3-pyridylcarbamoyl)indolines (Bromidge et al. J. Med. Chem. 1998, 41, 1598) from which they evolved. Compounds from this series showed excellent oral activity in a rat mCPP hypolocomotion model and in animal models of anxiety. On the basis of their favorable biological profile, 32 (SB-228357) and 40 (SB-243213) have been selected for further evaluation to determine their therapeutic potential for the treatment of CNS disorders such as depression and anxiety.
